Department of Thoracic Surgery, Zurich University Hospital, Zurich, Switzerland.
Division of Pulmonary Medicine, Zurich University Hospital, Zurich, Switzerland.
J Thorac Cardiovasc Surg. 2017 Dec;154(6):2135-2141. doi: 10.1016/j.jtcvs.2017.07.032. Epub 2017 Jul 29.
As large registries show an increased risk for lung transplant recipients aged 60 years or more, few single centers report favorable outcomes for carefully selected older recipients without providing essential details. The purpose of our study was to determine variables that influence survival in the elderly.
All adult bilateral first lung transplants between January 2000 and December 2014 were divided in 2 groups: those aged less than 60 years (N = 223) and those aged 60 years or more (N = 83). The Charlson-Deyo Index determined recipient comorbidities. The Oto Donor Score assessed donor lung quality.
Recipients aged 60 years or more had a significant lower median survival compared with their younger counterparts (48 vs 112 months, respectively, P < .001). Recipient age was as an exponentially increasing univariate risk factor for mortality. By adjusting for variables in multivariate analysis, this trend was nonsignificant. The displacing variables were idiopathic pulmonary fibrosis (hazard ratio [HR], 1.5; 95% confidence interval [CI], 1.0-2.2), Charlson-Deyo Index 2 or greater (HR, 1.3; 95% CI, 1.0-1.8), systemic hypertension (HR, 1.7; 95% CI, 1.2-2.6), gastroesophageal reflux (HR, 1.9; 95% CI, 1.1-3.1), diverticulosis (HR, 1.7; 95% CI, 1.0-2.7), and an Oto Donor Score 8 or greater (HR, 1.5; 95% CI, 1.1-2.0). All of these risk factors were significantly more likely to occur in recipients aged 60 years or more, except for a tendency for high Charlson-Deyo Index.
The comorbidity profile, underlying disease, and donor lung quality appear to be more important than age in reducing long-term survival. Older age serves as a marker for a complex constellation of factors that might be considered the relative or absolute contraindication to lung transplantation rather than age, per se.
由于大型注册研究显示,60 岁或以上的肺移植受者的风险增加,因此很少有单一中心报告精心挑选的老年受者的良好结果,而没有提供基本细节。我们研究的目的是确定影响老年人生存的变量。
2000 年 1 月至 2014 年 12 月期间,所有成人双侧首次肺移植分为 2 组:年龄小于 60 岁(N=223)和年龄 60 岁或以上(N=83)。Charlson-Deyo 指数确定受者合并症。Oto Donor 评分评估供肺质量。
60 岁或以上的受者中位生存时间明显低于年轻受者(分别为 48 个月和 112 个月,P<0.001)。受者年龄是单变量死亡风险的指数增加因素。通过多变量分析调整变量后,这种趋势无统计学意义。取代变量为特发性肺纤维化(HR,1.5;95%置信区间 [CI],1.0-2.2)、Charlson-Deyo 指数 2 或更高(HR,1.3;95%CI,1.0-1.8)、高血压(HR,1.7;95%CI,1.2-2.6)、胃食管反流(HR,1.9;95%CI,1.1-3.1)、憩室病(HR,1.7;95%CI,1.0-2.7)和 Oto Donor 评分 8 或更高(HR,1.5;95%CI,1.1-2.0)。除了 Charlson-Deyo 指数偏高的趋势外,所有这些危险因素在 60 岁或以上的受者中更有可能发生。
合并症谱、基础疾病和供肺质量似乎比年龄更重要,可降低长期生存率。年龄较大是多种复杂因素的标志,这些因素可能被视为肺移植的相对或绝对禁忌证,而不是年龄本身。